Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas
2021 ASCO Annual Meeting
Narjust Duma, MD, of the Carbone Cancer Center at the University of Wisconsin, Madison, and Gladys I. Rodriguez, MD, of South Texas Oncology and Hematology, talk about the underrepresentation of Hispanic individuals in medicine, especially in oncology, and their efforts to create the first Young Investigator Award in Recognition of an Outstanding Latina Researcher to encourage Hispanic women to enter medicine and cancer research.
The ASCO Post Staff
Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung cancer (Abstract 8500).
The ASCO Post Staff
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
The ASCO Post Staff
Pasi A. Janne, MD, PhD, of Dana-Farber Cancer Institute, discusses study findings that show patritumab deruxtecan is effective in patients with EGFR-mutated and inhibitor-resistant non–small cell lung cancer. Dr. Janne also explains why targeting HER3, a mutation expressed in most EGFR-altered cancers, is a beneficial treatment approach (Abstract 9007).
The ASCO Post Staff
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses health-related quality-of-life data from the phase III CLEAR trial, which compared lenvatinib plus pembrolizumab or everolimus vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (Abstract 4502).
The ASCO Post Staff
Martin Reck, MD, PhD, of LungenClinic, discusses a 2-year update of the CheckMate 9LA study, which sought to determine whether nivolumab plus ipilimumab combined with two cycles of chemotherapy is more effective than four cycles of chemotherapy alone as a first-line treatment for patients with stage IV non–small cell lung cancer (Abstract 9000).
